U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H19N3O6
Molecular Weight 385.3707
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NILVADIPINE

SMILES

COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C)C#N

InChI

InChIKey=FAIIFDPAEUKBEP-UHFFFAOYSA-N
InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3

HIDE SMILES / InChI
Molecular Formula C19H19N3O6
Molecular Weight 385.3707
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7898101

Nilvadipine (NIVADIL®) is a L-type calcium channel blocker for treatment of hypertension. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

CNS Activity

Originator

Approval Year

Unknown
134361
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
534
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
NIVADIL

Approved Use

Nivadil is indicated for the treatment of essential hypertension.

Launch Date

8.3790719E11
Primary
Phase III
663
Nilvadipine

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats.
1994 Nov
Effects of nilvadipine (a dihydropyridine-type calcium entry blocker) on cerebral blood flow in acute experimental brain ischemia in rats.
1996 Aug
Interaction of digoxin with antihypertensive drugs via MDR1.
2002 Feb 15
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
2004 Apr
Patents

Patents

JP3352095B2
17
JPH03123730A
1
US4338322
1

Sample Use Guides

In Vivo Use Guide
The recommended dose is 1 NIVADIL® 8 mg prolonged release capsule per day in the morning as a starting dose. If after 2 - 4 weeks of therapy an adequate anti-hypertensive effect is not achieved, a daily dose of 16 mg nilvadipine (2 x 8 mg NIVADIL® prolonged release capsules, or 1 x 16 mg NIVADIL® prolonged release capsule, in the morning) may improve the blood pressure response.
Route of Administration: Oral
In Vitro Use Guide
The cardiovascular effect of nilvadipine (FR34235) with the effects of nifedipine, nicardipine, and diltiazem on the dog using in vitro arterial strip preparations was compared. FR34235 reduced the amplitude of coronary arterial contraction induced by K+ more so than that induced by norepinephrine in in vitro preparations. The ID50 values of FR34235 for various arterial strips contracted by K+ were smaller (1/5-1/426) than those of nifedipine and diltiazem, and almost the same as those of nicardipine.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:47:56 UTC 2023
Edited
by admin
on Wed Jul 05 22:47:56 UTC 2023
Record UNII
0214FUT37J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NILVADIPINE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
FK 235
Code English
NILVADIPINE [JAN]
Common Name English
NIVADIL
Brand Name English
NIVADIPINE
Common Name English
NILVADIPINE [MART.]
Common Name English
NILVADIPINE [USAN]
Common Name English
nilvadipine [INN]
Common Name English
CL-287,389
Code English
SK&F-102362
Code English
3,5-PYRIDINEDICARBOXYLIC ACID, 2-CYANO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-METHYL 5-(1-METHYLETHYL) ESTER
Common Name English
ESCOR
Brand Name English
5-ISOPROPYL 3-METHYL 2-CYANO-1,4-DIHYDRO-6-METHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
CL 287,389
Code English
CL-287389
Code English
SK&F-102,362
Code English
(±)-NILVADIPINE
Common Name English
NIVADIP
Brand Name English
FK-235
Code English
NILVADIPINE [MI]
Common Name English
Nilvadipine [WHO-DD]
Common Name English
DL-NILVADIPINE
Common Name English
SKF-102362
Code English
FR-34235
Code English
SK&F 102,362
Code English
Classification Tree Code System Code
WHO-ATC C08CA10
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
WHO-VATC QC08CA10
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
NCI_THESAURUS C333
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID2046624
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
DRUG CENTRAL
1934
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
WIKIPEDIA
Nilvadipine
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
PUBCHEM
4494
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
USAN
W-82
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
MERCK INDEX
M7900
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY Merck Index
INN
5459
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
NCI_THESAURUS
C84019
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
FDA UNII
0214FUT37J
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
SMS_ID
100000083903
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
ChEMBL
CHEMBL517427
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
EVMPD
SUB09292MIG
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
DRUG BANK
DB06712
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
CAS
75530-68-6
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
RXCUI
53692
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY RxNorm
MESH
C035100
Created by admin on Wed Jul 05 22:47:56 UTC 2023 , Edited by admin on Wed Jul 05 22:47:56 UTC 2023
PRIMARY
Related Record Type Details
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1D
TARGET -> INHIBITOR
Related Record Type Details
Structure of NILVADIPINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966